Page 383 - Traité de Chimie Thérapeutique 4 Médicaments en relation avec des systèmes hormonaux

344 MÉDICAMENTS EN RELA TION A VEC DES SYSTÈMES HORMONAUX

TSUJITA Y. et al. "Pravastatin sodium : a novel cholestérol lowering agent that inhibits
HMG-CoA reductase" (1989) Cardiovascular Drug Reviews, 7 (2), 110-126.
YOSHINO G. et al. "Two-year study of the effect of pravastatin (CS-514) on plasma
lipoprotein and apolipoprotein concentration in hypercholesterolemic patients"
(1989) Outrent Therap Res, 46 (1), 144-152.
SINGHVI S.M. et al. “Disposition of pravastatin sodium, a tissue-selective HMG-CoA
reductase inhibitor in healthy subjects" (1990) Brit J Clin Pharmac, 29, 239-243.
Elisor, pravastatine (1992) CD-ROM Vidal, OVP, éditions du Vidal, 11 rue Quentin
Bauchard, 75008 Paris.
Etudes comparatives
WEISWEILER P. “Simvastatin and bézafibrate : effects on sérum lipoproteins and leci-
thin : cholestérol acyltransferase activity in familial hypercholesterolaemia" (1988)
EurJCIin Pharmacol, 35, 579-583.
ERKELENS D.W. et al. “Clinical expérience with simvastatin compared with cholesty-
ramine" (1988) Drugs, 36 (suppl 3), 87-92.
ENDO A. “Biochemistry and pharmacology of HMG-CoA reductase inhibitors" (1989)
Atherosclerosis VIII, 775-780.
GERMERSHAUSSEN J.l. et al. “Tissue selectivity of the cholestérol lowering agents
lovastatin, simvastatin and pravastatin in rats in vivo" (1989) Biochem and Biophys
Res Commun 158 (3), 667-675.
ERKELENS D.W. "Combination drug therapy with HMG-CoA reductase inhibitors and
bile acid séquestrants for hypercholesterolemia" (1990) Cardiology 77 (4), 33-38.
NAKANDAKARE E. et al. “Effects of simvastatin, bézafibrate and gemfibrozil on the
quantity and composition of plasma lipoproteins” (1990) Atherosclerosis 82, 211 -217.
FRICKER J. et al. “Efficacité et tolérance de la simvastatine et du fénofibrate dans
l'hypercholestérolémie primaire" (1990) La Presse Médicale 19 (42), 1927-1930.
ZIEGLER O. et al. “Safety, tolerability, and efficacy of simvastatin and fénofibrate ; a
multicenter study" (1990) Cardiology, 77 (suppl 4), 50-57.
PENTIKAINEN P.J. et al. "Comparative pharmacokinetics of lovastatin, simvastatin
and pravastatin in humans" (1992) J Clin Pharmacol, 32, 136-140.
DESLYPERE J.P. “Addition of fibrates to simvastatin therapy in hyperlipidaemic
patients" (1992) Atherosclerosis, 97, 567-571.
GLUECK C.J. "Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias”
(1992) Amer J Cardiol, 70 (1), 1 -9.
LECERF J.M. et al. "Comparaison de l'efficacité de la simvastatine et du gemfibrozil
dans l’hypercholestérolémie primaire" (1993) Rev Med Int 14 (4), 269-274.
HOGGERBRUGGE N. et al. "The efficacy and safety of pravastatin, compared to and
in combination with bile acid binding resins in familial hypercholesterolaemia"
(1990) J Intern Med 228, 261-266.
Perspectives
HURLEY T.R. "Photodecomposition of CI-981, an HMG-CoA reductase inhibitor"
(1993) Tetrahedron, 49 (10), 1979-1984.
SIT S.Y. et al. “Synthesis, biological profile and quantitative structure-activity relation-
ship of a sériés of novel 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibi­
tors’' (1990) J Med Chem, 33 (11), 2982-2999.